Efficacy of procaterol and montelukast on children with moderate persistent asthma / 中国基层医药

Objective To investigate the efficacy of procaterol and montelukast on lung function in children with moderate persistent asthma.Methods 86 children with moderate persistent asthma from January 2014 to December 2014 in our hospital were studied,and according to the random number table method,they were divided into the control group and the observation group,43 cases in each group.The observation group was treated with procaterol combined with montelukast,the control group was treated with procaterol.The cough relief and disappearance time,the improvement of pulmonary function after treatment,the clinical effect and the control of asthma after one month of the two groups were compared.Results After treatment,children cough relief and disappeared time of the observation group was significantly shorter than the control group (t =4.418 5,3.784 4,P =0.000 0,0.000 3).After treatment, the pulmonary function was found to improve the situation of the observation group being good than the control group, PEF,FVC,FEV1 ,FEV1 /FVC predicted values were significantly higher than the control group (all P <0.05).The total effective rate of the observation group (93.00%)was significantly higher than 74.40% of the control group (u =2.223 2,P =0.026 2).After one month of treatment,the basic control rate of the observation group(88.37%) was significantly higher than 67.40% of the control group(u =2.386 6,P =0.017 0).The incidence rate of adverse reactions of the observation group (6.98%)was significantly lower than 51.16% of the control group(P <0.05). Conclusion Procaterol combined with montelukast in the treatment of children with moderate persistent bronchial asthma can improve clinical efficacy,safety,and improve symptom control rate,it is worthy of promotion.

Effect of Indacaterol on Cough and Phlegm in Chronic Obstructive Pulmonary Disease Patients: A Meta-Analysis of Five Randomized Controlled Trials

We investigated the effects of indacaterol on cough and phlegm in patients with stable chronic obstructive pulmonary disease (COPD). We performed a meta-analysis with five randomized controlled trials (RCTs) of indacaterol in stable COPD patients. The symptom severity was defined using the St. George's Respiratory Questionnaire (SGRQ). We analyzed patients treated with 150 microg (n = 945) and 300 microg (n = 832) out of 3,325 patients who completed the SGRQ from five RCTs. After a 12-week treatment of 150 microg indacaterol, cough improvement was reported in 36.5% (316/866) of patients treated with indacaterol vs. 32.2% (259/804) patients treated with placebo (Relative Ratio [RR], 1.13; 95% confidence interval [CI], 0.99-1.29). Phlegm improvement was reported in 31.0% (247/798) of patients treated with indacaterol vs. 30.6% (225/736) of patients treated with placebo (RR, 1.01; 95% CI, 0.87-1.18). Dyspnea improvement was reported in 39.5% (324/820) of patients treated with indacaterol vs. 31.5% (237/753) patients treated with placebo (RR, 1.33; 95% CI, 1.03-1.71; P = 0.001, I2 = 55.1%). Only dyspnea improvement was significant compared to placebo even at the 300 microg indacaterol dose. Compared to placebo, a 12-week treatment of the long-acting beta-agonist, indacaterol might not have a significant effect on cough or phlegm in stable COPD.

Clinical efficacy of montelukast sodium and procaterol for treating the children with chronic cough and its impact on serum immunoglobulin E / 中国医师进修杂志

Objective To investigate the clinical efficacy of montelukast sodium and procaterol for treating the children with chronic cough and its impact on serum immunoglobulin E(IgE).Methods Eighty cases of children with chronic cough were divided into treatment group and control group by random digits table method with 40 cases each.The control group was given procaterol treatment on the basis of conventional treatment,and the treatment group was added montelukast sodium on the basis of treatment of control group.Treatment course was 1 month.Before and after treatment,the clinical symptoms and signs in the two groups were observed,the serum IgE level was detected,the clinical efficacy was evaluated,and the adverse reaction was observed.Results The total effective rate in the treatment group was 95.0％ (38/40),the control group was 67.5％ (27/40),and the difference was significant (x2 =9.928,P ＜ 0.01).The time of cough mitigation and disappearance in the treatment group was (24.41 ± 8.14) d and (41.27 ± 14.74) d,which was lower than that in the control group [(47.27 ± 15.76) d and (57.78 ±20.64) d],and the difference was significant (t =8.153,4.118,P ＜ 0.05).After treatment,the serum IgE level in the treatment group and control group significantly decreased [(295.27 ± 105.45)μg/L vs.(594.48 ± 198.16)μg/L,(427.78 ± 152.78) μ g/L vs.(567.21 ± 189.07) μ g/L,t =8.430,3.628,P ＜ 0.05],and the difference was significant between them (t =4.515,P ＜0.05).There were no serious adverse reactions in two groups.Conclusions The serum IgE may play an important role in the incidence of children with chronic cough,and montelukast sodium and procaterol for treating the children with chronic cough is safe,effective and worthy of clinical application.